GLP-1 and Kidney Protection: The FLOW Trial Data

The FLOW trial's results — and semaglutide's subsequent FDA approval for chronic kidney disease — represent one of the most significant expansions of GLP-1 indications. For the first time, a weight loss medication is approved to protect kidney function.

FLOW Trial Results

The FLOW trial enrolled patients with type 2 diabetes and chronic kidney disease. Semaglutide demonstrated significant reductions in kidney function decline (measured by eGFR slope), reduced the composite endpoint of sustained eGFR decline, kidney failure, or death from kidney or cardiovascular causes, and showed kidney-specific benefits independent of glycemic control or weight loss.

The Cardiorenal Connection

Heart and kidney disease frequently co-occur — a relationship called cardiorenal syndrome. Semaglutide is now FDA-approved for both cardiovascular risk reduction (SELECT trial) and chronic kidney disease (FLOW trial), making it the first medication with formal indications protecting both organs simultaneously in patients with obesity.

Population Impact

Approximately 37 million Americans have chronic kidney disease, and obesity is a major risk factor. Many of these patients also have cardiovascular disease and type 2 diabetes. Semaglutide's overlapping indications mean that a single medication can address multiple comorbidities — simplifying treatment regimens and potentially improving adherence.